Danaher Corp (DHR)

How it makes money

Danaher sells an installed base of equipment and instruments and then earns most of its money from what that installed base consumes: reagents, cell culture media, chromatography resins, filters, antibodies, test cartridges, plus service contracts and software. The 2025 annual report states that 82% of revenues were recurring and 18% non-recurring, with the recurring share at 88% in Biotechnology, 89% in Diagnostics and 66% in Life Sciences. In practice the equipment is the entry point and the consumable stream that follows it, often written into a customer's validated manufacturing or clinical process, is the business.

Revenue by segment

Danaher's advantage rests on how hard its consumables are to remove once adopted. A bioprocessing resin, filter or culture medium is written into a drug maker's regulated manufacturing process and changing it can mean re-validation and regulatory filings; a diagnostics instrument in a hospital lab runs on its own proprietary test cartridges. The financial trace of this is in the filing itself: 82% of 2025 revenues were recurring, 88% in Biotechnology and 89% in Diagnostics. The 10-K is candid that the company still faces intense competition and that its growth depends on developing and commercialising new products, so the advantage is not absolute — it is strongest where the customer's own process is locked around Danaher's consumable.

The three segments behave differently over the cycle. Diagnostics follows testing volumes in hospitals and laboratories, which move with population health needs more than with the economy, and the company reports 89% of that segment's revenue as recurring. Biotechnology follows how much biological medicine is actually being manufactured, plus how freely pharmaceutical and biotech customers are spending on capacity and inventory — a driver that swings, and whose swing shows up first in orders for equipment rather than in consumables. Life Sciences is the most exposed to capital spending: it has the lowest recurring share, 66%, and depends on instrument purchases by academic, government and industrial laboratories, which are postponed when research budgets tighten. The company itself lists conditions in the global economy, healthcare cost-reduction pressure and geopolitical factors among the things that can hurt results.

Key risks

• Conditions in the global economy and in the markets served — The company states that conditions in the global economy, in the particular markets it serves and in financial markets can adversely affect its business and financial statements.
• Intense competition — Danaher says it faces intense competition and that, if unable to compete effectively, it may experience decreased demand and decreased market share.
• Dependence on new product development — Growth depends on the timely development and commercialisation, and on customer acceptance, of new and enhanced products and services based on technological innovation.
• Cost pressure in healthcare — The healthcare industry and related industries the company serves are undergoing significant changes to reduce, and make more predictable, their costs, which can adversely affect Danaher's business and financial statements.
• Geopolitical, political and compliance factors — Economic, political, geopolitical, legal, compliance, social and business factors — including the impact of military conflicts — both inside and outside the United States can negatively affect the business and financial statements.
• Artificial intelligence — The company flags that uncertainties in the development, deployment and use of artificial intelligence in its business and its products may result in harm to its business and reputation.
• Acquisitions and divestitures — Risks include an inability to consummate acquisitions at the historical rate and at appropriate prices, difficulties in integrating what is acquired, and divestitures or other dispositions that could negatively impact the business — including tax liabilities arising from spin-offs.
• IT systems and security breaches — Significant disruptions in, or breaches in the security of, the company's information technology systems are disclosed as an operational risk.
• Product defects and manufacturing problems — Defects, manufacturing problems, unanticipated use of products or inadequate disclosure about them are disclosed as a risk — a live issue for a company selling regulated medical devices and diagnostics.
• Cost and availability of supplies — Financial results are subject to fluctuations in the cost and availability of supplies, alongside dependence on business partners and other third parties for the development, supply or marketing of certain products and technologies.
• Intellectual property — Any inability to adequately protect its intellectual property, or to avoid third-party infringement claims, is disclosed as a risk; the filing also notes government rights over certain IP.
• Debt, currency and goodwill — Outstanding debt has at times increased significantly as a result of acquisitions; results can also be affected by foreign currency exchange rates, by tax liabilities and by goodwill impairment.
• Regulation, litigation and environmental liability — The company discloses risks from changes in regulation, from litigation, from medical device regulation specifically, and from environmental liabilities.
• Global health crises — Global health crises, pandemics, epidemics or other outbreaks can adversely impact certain elements of the business and financial statements.

The 2025 10-K does not disclose a customer concentration figure: there is no statement that any single customer accounted for a stated percentage of revenues, and no top-customer table. What the filing does describe is a customer base spread across pharmaceutical and biotechnology companies, contract manufacturers, academic and government laboratories, hospitals, physicians' offices and reference laboratories, in the United States and abroad. The filing does state that no single supplier is material to the company, but that is about suppliers, not customers. Read this as 'not disclosed' rather than as evidence of low concentration.